International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). - Wikidata - awgldk - TriplyDB

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

http://www.wikidata.org/entity/Q37228051

about

Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.Prognostic value of routine laboratory variables in prediction of breast cancer recurrence Using a novel T-lymph node ratio model to evaluate the prognosis of nonmetastatic breast cancer patients who received preoperative radiotherapy followed by mastectomy: An observational study.

P2860

Q36577603-F23DF452-B3B5-4369-A8D4-634D156310E0 Q37725620-CBED9B67-C070-45FD-8741-C7AA9694FDB5 Q41421740-A70B34D4-8EE8-47BC-AFF0-FAF01587DC8D Q47094712-09E758A4-18C3-461E-821F-F9484AEC7422

P2860

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

http://www.wikidata.org/entity/Q37228051

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@en

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@nl

type

label

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@en

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@nl

prefLabel

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@en

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@nl

P1433

Q37228051-2E77263C-CBD3-429F-8C48-5C9BF49236B1

P1476

Q37228051-291387D1-8BAB-4C9E-B379-F0E834266B95

P2093

Q37228051-01637A67-A491-4511-BD3C-D62B4CDCCB7C

Q37228051-06BC5BFA-80A6-482F-BDA0-7B3A8C97B7E2

Q37228051-0C70D1AE-6A17-418E-BE2C-8B2BE75E492E

Q37228051-2C4A5038-47AA-4E87-A92A-1A6F78B6EE62

Q37228051-4931563B-A910-43E0-81B3-28185EDE0C5A

Q37228051-57B550B3-1FAF-4F06-8204-F07BB323BD71

Q37228051-5A10C267-C92D-45C4-97B2-101A817D491E

Q37228051-6830BB7C-EB9D-47C0-A8A4-DEF1D7B44F92

Q37228051-6A454BDE-2303-4DA1-AC3D-8BD87F00125B

Q37228051-6F646A24-3F08-43D2-897B-753F2779A678

P2860

Q37228051-069C7B91-1F26-48D1-86D6-5DA13C86308F

Q37228051-071D8BD7-5A66-465F-A647-0118244264FE

Q37228051-166FD8EC-642C-403C-8A95-1137642E5832

Q37228051-1A802A09-7D98-49A3-85AA-CE8F26E1B22C

Q37228051-1C2FD0B3-2102-4C05-87CE-E63E3B8D45C1

Q37228051-292E288D-8602-46D3-84B3-8622AC079F83

Q37228051-30CDC231-F18D-49F7-85FA-516B67B384F2

Q37228051-37403C70-716D-4810-834C-EF0FE1F4364A

Q37228051-37B831A3-731B-4D58-AFC1-9E24B2309ACD

Q37228051-38A640DF-0C7F-4AF6-A937-50156BA076CB

P304

Q37228051-1A2788D1-EA29-448B-B6E6-6D0B1308F8AE

P31

Q37228051-0CC90473-4E66-409F-BDF8-AEA9FF2C974F

P356

Q37228051-3ABF05CC-8A52-4BBA-8226-4EDCCBC279E3

P433

Q37228051-23C6FAE9-507E-4518-BCD3-65EB9B23C60C

P478

Q37228051-72383364-92A8-4650-A142-2EA230365E0C

P50

Q37228051-0A640D35-DF8F-462D-8B49-E218506F1D1B

Q37228051-23CAE867-998F-4975-AC94-D06C87041043

Q37228051-335C2157-6C68-44F0-A259-DC07A22D2F33

Q37228051-344BD237-AC4D-4DE3-9452-34ABD9CEAD10

Q37228051-7D69D33B-9DF6-4C4C-8949-166EA93442F2

Q37228051-84FDB9BD-E880-4DE4-93C7-E03D4320DB12

Q37228051-9C47792C-82FD-49E8-9A62-6094D29A4103

Q37228051-A4E8FF34-7E91-442B-8C4A-A9E9AF9856F0

Q37228051-D20186D2-4023-409C-8CEB-52158F10CFB6

Q37228051-D5F213FC-929B-47A8-AC57-821430903F71

P577

Q37228051-82B3735E-AF09-47E1-95FB-CF9FF53305E5

P5875

Q37228051-5D757CF4-F4BC-405D-982A-87BAD20A05D1

P698

Q37228051-CE99470F-0886-4A46-A52C-016A10F24946

P921

Q37228051-621A94C1-73E6-4866-9D13-CA70EB29A263

P932

Q37228051-D6B2F681-982D-473A-A165-74667663C04F

P356

P1433

Journal of the National Cancer Institute Monographs

P1476

International Expert Consensus ...... Cancer, Cremona, Italy (2013).

@en

P2093

Alberto Bottini

http://www.w3.org/2001/XMLSchema#string

Alfredo Berruti

http://www.w3.org/2001/XMLSchema#string

Andrea Ravelli

http://www.w3.org/2001/XMLSchema#string

Andreas Makris

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Daniele Generali

http://www.w3.org/2001/XMLSchema#string

Edda L Simoncini

http://www.w3.org/2001/XMLSchema#string

Fraser Symmans

http://www.w3.org/2001/XMLSchema#string

Gaia Schiavon

http://www.w3.org/2001/XMLSchema#string

Gunter Von Minckwitz

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

P304

90-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCIMONOGRAPHS/LGV023

http://www.w3.org/2001/XMLSchema#string

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

Serena Di Cosimo

Maria Grazia Daidone

Giuseppe Curigliano

Kerstin Hermelink

Michael A. Jacobs

Christos Hatzis

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278042330

http://www.w3.org/2001/XMLSchema#string

P698

26063896

http://www.w3.org/2001/XMLSchema#string

P921

P932

5009414

http://www.w3.org/2001/XMLSchema#string